Professional Documents
Culture Documents
04
Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IG
https://creativecommons.org/licenses/by-nc-sa/3.0/igo).
Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided
In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or service
adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create
following disclaimer along with the suggested citation: “This translation was not created by the World Health Organizati
or accuracy of this translation. The original English edition shall be the binding and authentic edition”.
Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules o
(http://www.wipo.int/amc/en/mediation/rules/).
Suggested citation. WHO Access, Watch, Reserve (AWaRe) classification of antibiotics for evaluation and monitoring of u
(WHO/HMP/HPS/EML/2021.04). Licence: CC BY-NC-SA 3.0 IGO.
Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for
see http://www.who.int/about/licensing.
Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figu
whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resu
component in the work rests solely with the user.
General disclaimers. The designations employed and the presentation of the material in this publication do not imply th
of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimita
dashed lines on maps represent approximate border lines for which there may not yet be full agreement.
The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or reco
similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguish
All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, th
warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies w
damages arising from its use.
This publication contains the collective views of an international group of experts and does not necessarily represent th
onCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO;
dance with the mediation rules of the World Intellectual Property Organization
r evaluation and monitoring of use, 2021. Geneva: World Health Organization; 2021
korders. To submit requests for commercial use and queries on rights and licensing,
n this publication do not imply the expression of any opinion whatsoever on the part
ities, or concerning the delimitation of its frontiers or boundaries. Dotted and
e full agreement.
To assist in the development of tools for antibiotic stewardship at local, national and global levels and to reduce antimicrobial resistance, the Access, Watch,
Reserve (AWaRe) classification of antibiotics was developed – where antibiotics are classified into different groups to emphasize the importance of their
appropriate use.
This classification is intended to be used as a tool for countries to better support antibiotic monitoring and stewardship activities. It is not intended as model for
the inclusion of antibiotics on national essential medicine lists. Antibiotics classified under AWaRe and also included on the WHO Model Lists of Essential
Medicines are indicated in the worksheets.
This group includes antibiotics and antibiotic classes that should be reserved for treatment of confirmed or suspected infectio
to multi-drug-resistant organisms. Reserve group antibiotics should be treated as “last resort” options.
Selected Reserve group antibiotics are listed as individual medicines on the WHO Model Lists of Essential Medicines when the
a favourable risk-benefit profile and proven activity against “Critical Priority” or “High Priority” pathogens identified by the WH
Priority Pathogens List1, notably carbapenem resistant Enterobacteriaceae. These antibiotics should be accessible, but their us
should be tailored to highly specific patients and settings, when all alternatives have failed or are not suitable.
These medicines could be protected and prioritized as key targets of national and international stewardship programs involvin
monitoring and utilization reporting, to preserve their effectiveness.
1 WHO Priority Pathogens List
Antibiotic Class ATC code Category
Aztreonam Monobactams J01DF01 Reserve
Carumonam Monobactams J01DF02 Reserve
Cefiderocol Other-cephalosporins J01DI04 Reserve
Ceftaroline-fosamil Fifth-generation cephalosporins J01DI02 Reserve
Ceftazidime/avibactam Third-generation-cephalosporins J01DD52 Reserve
Ceftobiprole-medocaril Fifth-generation cephalosporins J01DI01 Reserve
Ceftolozane/tazobactam Fifth-generation cephalosporins J01DI54 Reserve
Colistin_IV Polymyxins J01XB01 Reserve
Colistin_oral Polymyxins A07AA10 Reserve
Dalbavancin Glycopeptides J01XA04 Reserve
Dalfopristin/quinupristin Streptogramins J01FG02 Reserve
Daptomycin Lipopeptides J01XX09 Reserve
Eravacycline Tetracyclines J01AA13 Reserve
Faropenem Penems J01DI03 Reserve
Fosfomycin_IV Phosphonics J01XX01 Reserve
Iclaprim Trimethoprim-derivatives J01EA03 Reserve
Imipenem/cilastatin/relebact Carbapenems J01DH56 Reserve
Lefamulin Pleuromutilin J01XX12 Reserve
Linezolid Oxazolidinones J01XX08 Reserve
Meropenem/vaborbactam Carbapenems J01DH52 Reserve
Minocycline_IV Tetracyclines J01AA08 Reserve
Omadacycline Tetracyclines J01AA15 Reserve
Oritavancin Glycopeptides J01XA05 Reserve
Plazomicin Aminoglycosides J01GB14 Reserve
Polymyxin-B_IV Polymyxins J01XB02 Reserve
Polymyxin-B_oral Polymyxins A07AA05 Reserve
Tedizolid Oxazolidinones J01XX11 Reserve
Telavancin Glycopeptides J01XA03 Reserve
Tigecycline Glycylcyclines J01AA12 Reserve
firmed or suspected infections due
tions.
ssential Medicines when they have
thogens identified by the WHO
ld be accessible, but their use
not suitable.
ewardship programs involving
Antibiotic
acetylspiramycin/metronidazole
amikacin/cefepime
amoxicillin/bacillus coagulans/cloxacillin
amoxicillin/bacillus coagulans/dicloxacillin
amoxicillin/clavulanic acid/lactic ferments
amoxicillin/clavulanic acid/lactobacillus acidophilus
amoxicillin/clavulanic acid/nimesulide
amoxicillin/cloxacillin
amoxicillin/cloxacillin/lactic acid
amoxicillin/cloxacillin/lactobacillus acidophilus/serrapeptase
amoxicillin/cloxacillin/lactobacillus lactis
amoxicillin/cloxacillin/serrapeptase
amoxicillin/dicloxacillin
amoxicillin/dicloxacillin/saccharomyces boulardii
amoxicillin/flucloxacillin
amoxicillin/flucloxacillin/lactobacillus acidophilus
amoxicillin/metronidazole
amoxicillin/pivsulbactam
amoxicillin/sulbactam
ampicillin/bacillus coagulans/cloxacillin
ampicillin/cloxacillin
ampicillin/cloxacillin/lactobacillus acidophilus
ampicillin/cloxacillin/saccharomyces boulardii
ampicillin/dicloxacillin
ampicillin/dicloxacillin/lactobacillus acidophilus
ampicillin/flucloxacillin
ampicillin/lidocaine/sulbactam
ampicillin/oxacillin
ampicillin/sultamicillin
ascorbic acid/metamizole sodium/penicillin g /streptomycin
azithromycin/cefixime
azithromycin/cefixime/lactobacillus acidophilus
azithromycin/cefpodoxime proxetil
azithromycin/fluconazole/secnidazole
azithromycin/levofloxacin
azithromycin/ofloxacin
benzyl penicillin/streptomycin
bromelains/doxycycline/lactobacillus reuteri/lactobacillus rhamnosus/ornidazole
bromhexine/sulfamethoxazole/trimethoprim
cefaclor/clavulanic acid
cefadroxil/clavulanic acid
cefadroxil/trimethoprim
cefalexin/trimethoprim
cefdinir/clavulanic acid
cefepime/sulbactam
cefepime/tazobactam
cefixime/cefpodoxime proxetil
cefixime/clavulanic acid
cefixime/clavulanic acid/lactobacillus acidophilus
cefixime/cloxacillin
cefixime/cloxacillin/lactobacillus acidophilus
cefixime/dicloxacillin
cefixime/lactobacillus acidophilus/ofloxacin
cefixime/levofloxacin
cefixime/linezolid
cefixime/moxifloxacin
cefixime/ofloxacin
cefixime/ornidazole
cefoperazone/sulbactam
cefoperazone/tazobactam
cefotaxime/sulbactam
cefpodoxime proxetil/clavulanic acid
cefpodoxime proxetil/cloxacillin/lactobacillus acidophilus
cefpodoxime proxetil/dicloxacillin
cefpodoxime proxetil/dicloxacillin/lactobacillus acidophilus
cefpodoxime proxetil/levofloxacin
cefpodoxime proxetil/ofloxacin
cefpodoxime proxetil/sulbactam
ceftazidime/sulbactam
ceftazidime/tazobactam
ceftazidime/tobramicin
ceftibuten/clavulanic acid
ceftriaxone/sulbactam
ceftriaxone/tazobactam
ceftriaxone/vancomycin
cefuroxime axetil/clavulanic acid
cefuroxime axetil/linezolid
cefuroxime axetil/sulbactam
cefuroxime/clavulanic acid
cefuroxime/sulbactam
chloramphenicol/tetracycline
ciprofloxacin/metronidazole
ciprofloxacin/ornidazole
ciprofloxacin/tinidazole
doxycycline/tinidazole
erythromycin/sulfamethoxazole/trimethoprim
erythromycin/trimethoprim
fosfomycin/trimethoprim
gatifloxacin/ornidazole
kanamycin/penicillin g
levofloxacin/metronidazole
levofloxacin/ornidazole
meropenem/sodium/sulbactam
meropenem/sulbactam
metronidazole/norfloxacin
metronidazole/spiramycin
metronidazole/tetracycline
mezlocillin/sulbactam
ofloxacin/ornidazole
oleandomycin/tetracycline
piperacillin/sulbactam
rifampicin/trimethoprim
sulfadiazine/sulfamethoxazole/trimethoprim
Antibiotics on 22nd WHO Model List of Essential Medicines 2021
Section 6.2.1 Access group antibiotics
Section 6.2.2 Watch group antibiotics
Section 6.2.3 Reserve group antibiotics
Antibiotic Class
Amikacin Aminoglycosides
Amoxicillin Penicillins
Amoxicillin/clavulanic-acid Beta-lactam/beta-lactamase-inhibitor
Ampicillin Penicillins
Azithromycin Macrolides
Benzathine-benzylpenicillin Penicillins
Benzylpenicillin Penicillins
Cefalexin First-generation-cephalosporins
Cefazolin First-generation-cephalosporins
Cefiderocol Other-cephalosporins
Cefixime Third-generation-cephalosporins
Cefotaxime Third-generation-cephalosporins
Ceftazidime Third-generation-cephalosporins
Ceftazidime/avibactam Third-generation-cephalosporins
Ceftriaxone Third-generation-cephalosporins
Cefuroxime Second-generation-cephalosporins
Chloramphenicol Amphenicols
Ciprofloxacin Fluoroquinolones
Clarithromycin Macrolides
Clindamycin Lincosamides
Cloxacillin Penicillins
Colistin_IV Polymyxins
Doxycycline Tetracyclines
Fosfomycin_IV Phosphonics
Gentamicin Aminoglycosides
Linezolid Oxazolidinones
Meropenem Carbapenems
Meropenem/vaborbactam Carbapenems
Metronidazole_IV Imidazoles
Metronidazole_oral Imidazoles
Nitrofurantoin Nitrofuran-derivatives
Phenoxymethylpenicillin Penicillins
Piperacillin/tazobactam Beta-lactam/beta-lactamase-inhibitor_anti-pseudomonal
Plazomicin Aminoglycosides
Polymyxin-B_IV Polymyxins
Procaine-benzylpenicillin Penicillins
Spectinomycin Aminocyclitols
Sulfamethoxazole/trimethoprim Sulfonamide-trimethoprim-combinations
Trimethoprim Trimethoprim-derivatives
Vancomycin_IV Glycopeptides
Vancomycin_oral Glycopeptides
nes 2021
Antibiotic Class
Amikacin Aminoglycosides
Amoxicillin Penicillins
Amoxicillin/clavulanic-acid Beta-lactam/beta-lactamase-inhibitor
Ampicillin Penicillins
Azithromycin Macrolides
Benzathine-benzylpenicillin Penicillins
Benzylpenicillin Penicillins
Cefalexin First-generation-cephalosporins
Cefazolin First-generation-cephalosporins
Cefixime Third-generation-cephalosporins
Cefotaxime Third-generation-cephalosporins
Ceftazidime Third-generation-cephalosporins
Ceftazidime/avibactam Third-generation-cephalosporins
Ceftriaxone Third-generation-cephalosporins
Cefuroxime Second-generation-cephalosporins
Chloramphenicol Amphenicols
Ciprofloxacin Fluoroquinolones
Clarithromycin Macrolides
Clindamycin Lincosamides
Cloxacillin Penicillins
Colistin_IV Polymyxins
Doxycycline Tetracyclines
Fosfomycin_IV Phosphonics
Gentamicin Aminoglycosides
Linezolid Oxazolidinones
Meropenem Carbapenems
Metronidazole_IV Imidazoles
Metronidazole_oral Imidazoles
Nitrofurantoin Nitrofuran-derivatives
Phenoxymethylpenicillin Penicillins
Piperacillin/tazobactam Beta-lactam/beta-lactamase-inhibitor_anti-pseudomonal
Polymyxin-B_IV Polymyxins
Procaine-benzylpenicillin Penicillins
Sulfamethoxazole/trimethoprim Sulfonamide-trimethoprim-combinations
Trimethoprim Trimethoprim-derivatives
Vancomycin_IV Glycopeptides
Vancomycin_oral Glycopeptides
es for Children 2021